Exploring the Potential of CAR-T Cells in Cancer Treatment

This chapter delves into the evolution and success of CAR-T cells in targeting malignant B cells in lymphoma and multiple myeloma using specific surface markers like CD20, CD19, and BCMA. It explains the process of engineering T cells with chimeric receptors to recognize and target cancer cells, highlighting the transformation in patient outcomes. The chapter also discusses the challenges and complexities in preparing patients for CAR-T therapy and the potential of using CAR-T cells in targeting virus-infected cells and autoreactive B cells in autoimmune diseases.